12 October 2021>: Original Paper
Prognostic Role of Serum Albumin Level in Patients with Lymphoma Undergoing Autologous Stem Cell Transplantation
Chengxin Luo 12CDE , Qingrong Li 12B , Xi Li 3B , Guixian Wu 12B , Xiangtao Huang 12B , Yali Zhang 12B , Yanni Ma 12B , Mingling Xie 12B , Yanni Sun 12B , Yarui Huang 12B , Zhen Huang 12B , Shuangnian Xu 12AEG* , Jieping Chen 12AEG*DOI: 10.12659/AOT.933365
Ann Transplant 2021; 26:e933365
Table 4 Results of univariate and multivariate Cox regression analyses for progression-free survival in the B-cell non-Hodgkin lymphoma subgroup.
Characteristics | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|
HR (95%CI) | P | HR (95%CI) | P | |
Male | 2.07 (0.87–4.91) | 0.100 | ||
Age >60 | 3.37 (1.41–8.06) | 0.006* | 4.06 (1.67–9.86) | 0.002* |
BMI | 0.04 (0.00–13.61) | 0.283 | ||
ECOG PS 2–3 | 1.75 (0.81–3.80) | 0.154 | ||
Ann Arbor stage III–IV | 1.47 (0.85–2.57) | 0.172 | ||
B symptoms | 0.99 (0.45–2.22) | 0.988 | ||
IPI risk | ||||
Low | 1.00 | |||
Low-intermediate | 1.46 (0.52–4.15) | 0.474 | ||
High-intermediate | 1.68 (0.51–5.53) | 0.390 | ||
High | 3.39 (1.13–10.18) | 0.029* | ||
LDH elevation (>240 U/L) | 2.52 (1.18–5.40) | 0.017* | ||
Bone marrow involvement | 3.09 (1.16–8.24) | 0.024* | ||
Prior regimens | ||||
1.00 | ||||
5–10 | 1.40 (0.60–3.25) | 0.432 | ||
≥10 | 1.11 (0.53–2.35) | 0.783 | ||
Rituximab induction | 0.96 (0.44–2.09) | 0.909 | ||
PR or NR | 2.65 (1.21–5.80) | 0.015* | ||
Disease duration | 1.00 (0.98–1.02) | 0.711 | ||
Albumin | 3.29 (1.47–7.37) | 0.004* | 3.22 (1.42–7.29) | 0.005* |
TP | 2.81 (1.26–6.27) | 0.012* | ||
Globulin level | 0.95 (0.87–1.03) | 0.186 | ||
Albumin/globulin ratio | 0.90 (0.29–2.82) | 0.862 | ||
Conditioning regimen | ||||
BEAM | 1.00 | |||
BEAC | 1.23 (0.36–4.24) | 0.738 | ||
CBV | 1.05 (0.32–3.50) | 0.935 | ||
CHOP-like | 0.75 (0.20–2.80) | 0.667 | ||
Dose of infused mononuclear cells | 0.97 (0.81–1.16) | 0.712 | ||
Maintenance therapy | 1.12 (0.50–2.49) | 0.782 | ||
* B-NHL – B-cell non-Hodgkin lymphoma; BEAC – carmustine, etoposide, cytarabine, and cyclophosphamide; BEAM – carmustine, etoposide, cytarabine, and melphalan; BMI – body mass index; CHOP – cyclophosphamide, anthracycline, vincristine, and prednisone; CBV – cyclophosphamide, carmustine, and etoposide; CR – complete remission; ECOG PS – Eastern Cooperative Oncology Group performance status; HL – Hodgkin lymphoma; HR – hazard ratio; IPI – international prognostic index; LDH – lactate dehydrogenase; NHL – non-Hodgkin lymphoma; NR – no response; PFS – progression-free survival; PR – partial remission; TP – total protein. |